Boehringer Ingelheim.
German pharmaceutical company
- Reports this week
- 3
- Active events
- 1
- Connections
- 142
What's happening
Active this week
Earlier this month
-
Matthew Hall serves as Executive Director of Corporate Development at Boehringer Ingelheim.Some support1 report
-
ACCESS Health International convened a health forum in the Philippines, which was supported by Boehringer Ingelheim.Some support1 report
-
Microsoft and Boehringer Ingelheim announced a partnership to explore digital patient twins for clinical development.Some support1 report
-
Boehringer Ingelheim formed a new committee including the American Liver Foundation, American Gastroenterological Association, and several key individuals.Some support1 report
-
Boehringer supplies vaccines to England and collaborates with the VMD, leading to disease spread into Scotland.Some support3 reports
One to three months ago
-
AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.Some support1 report
-
Boehringer Ingelheim and Nanyang Technological University have established a new research collaboration agreement.Some support1 report
-
Boehringer Ingelheim and SLR Consulting have partnered to develop an energy transformation programme.Some support2 reports
-
A foundation, involving Boehringer Ingelheim, addresses malnutrition and health issues in Colombia through social innovation hubs.Some support1 report
-
Sheila Denton was appointed as General Counsel & Corporate Secretary at Boehringer Ingelheim.Some support1 report
-
Boehringer Ingelheim and Palatin Technologies reported $13.2 million in revenue from their Fiscal 2026 collaboration.Some support1 report
-
Boehringer Ingelheim reminds pet owners about preventive care in the Philippines.Some support1 report
-
Commission approved Boehringer storage structure plans and safety improvements for a railroad crossing.Some support1 report
-
AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.Some support1 report
-
Boehringer Ingelheim opened a new U.S. Animal Health headquarters in Gainesville and continues to invest in Georgia operations.Some support1 report
-
WEG S.A., a Brazilian electric motor manufacturer, is linked to wealth derived from an inherited stake.Some support1 report
Gone quiet
No new reports in 90+ days-
GSK and Boehringer Ingelheim are facing product liability claims regarding Zantac.Some support1 report
-
NHS partners with Boehringer Ingelheim to focus on a CKD early detection scheme.Some support1 report
-
American Lung Association received financial support from Boehringer Ingelheim and launched an awareness campaign.Some support1 report
-
Major pharmaceutical companies, including Eli Lilly, AstraZeneca, and Boehringer Ingelheim, are adjusting investments and operations in Europe.Some support1 report1 development inside
-
Boehringer Ingelheim and Immunai announced a collaboration focused on T-cell targets for drug discovery.Some support1 report
-
Boehringer Ingelheim is seeking first-in-class assets in Korea.Some support1 report
-
Boehringer Ingelheim announced a partnership with Americares that aims to improve global access to medicine.Some support1 report
-
Proposed German drug pricing legislation is causing investment cuts and expansion cancellations for pharmaceutical companies.Some support2 reports1 development inside
-
German drug pricing policy creates investment risk for pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim.Some support1 report
-
German drug pricing reform is causing Eli Lilly and Boehringer Ingelheim to withdraw from European markets.Some support1 report
-
Dr. Kirk Shepard joined BP Logix's Life Sciences Strategic Advisory Board, leveraging his extensive background in the pharmaceutical industry.Some support1 report
-
Elanco, Zoetis, and Boehringer Ingelheim are noted for their leadership in the veterinary dermatology market.Some support1 report
-
Jyothis George held leadership roles at Amgen, Novo Nordisk, and Boehringer Ingelheim, driving strategic decisions on target indications and clinical trials.Some support1 report
-
Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement, receiving FDA feedback on a Pre-IND Briefing Document.Some support1 report
-
The FDA approved the Oncomine Dx Target Test, which identifies candidates for Boehringer Ingelheim's HERNEXEOS.Well supported4 reports
-
Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Boehringer Ingelheim this week
News at the entities that move Boehringer Ingelheim most-
Athens StructuralDollar General opened a new store in Athens, providing community access.Moves Boehringer Ingelheim
-
Pfizer OperationalICICI Prudential Mutual Fund's portfolio includes top picks such as Bajaj Finserv, HDFC Bank, and Pfizer.Moves Boehringer Ingelheim
-
England TransactionalMet Office forecasts a cold snap in the UK, prompting UKHSA to issue health warnings for England.Moves Boehringer Ingelheim
-
Johnson & Johnson OperationalDuke Energy, Johnson & Johnson, Microsoft, and Welltower are large positions in the iShares MSCI USA Min Vol Factor ETF amid investor angst.Moves Boehringer Ingelheim
-
Korea OperationalTourism benefits in Korea are expanding geographically beyond the capital city of Seoul.Moves Boehringer Ingelheim
-
Colombia OperationalBrazil holds national university entrance exam while Colombia and its citizens observe public holidays on Nov 16.Moves Boehringer Ingelheim
Connections
The 30 strongest of 142, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Athens Structural
Boehringer Ingelheim maintains headquarters and manufacturing operations in Athens.
-
Pfizer Operational
Both Pfizer and Boehringer Ingelheim are actively competing in the development of improved GLP-1 drugs.
-
Angela Fitch Structural
Angela Fitch holds a formal role as a committee member within Boehringer Ingelheim.
-
England Transactional
Boehringer Ingelheim supplies vaccines to England.
-
Johnson & Johnson Operational
Johnson & Johnson and Boehringer Ingelheim actively compete in the drug delivery and prostate cancer therapy markets.
-
Matthew Hall Structural
Matthew Hall serves as Executive Director of Corporate Development at Boehringer Ingelheim.
-
SLR Consulting Operational
The two companies are partners in a program focused on developing a global energy and infrastructure transformation initiative.
-
Colombia Operational
Boehringer Ingelheim operates in Colombia through established social innovation hubs and strategic partnerships.
Show all 30 connections
-
Aman Rajpal Structural
Aman Rajpal is a member of a committee formed by Boehringer Ingelheim.
-
Hampshire Operational
The relationship is characterized by an ongoing partnership between the company and the regional National Health Service (NHS) infrastructure.
-
Veterinary Medicines Directorate Operational
Boehringer Ingelheim actively coordinates with the Veterinary Medicines Directorate to secure vaccine approval.
-
American Lung Association Structural
Boehringer Ingelheim provides financial support to the American Lung Association.
-
Jonathan Q Purnell Structural
Jonathan Q Purnell holds a formal role by serving on a committee formed by Boehringer Ingelheim.
-
American Liver Foundation Operational
Boehringer Ingelheim formed a committee that includes the American Liver Foundation.
-
Ridgefield Transactional
Boehringer Ingelheim is utilizing Ridgefield's services or location as part of approved storage structure plans.
-
Zealand Pharma Mentioned together
Both companies are noted for their progress in metabolic strategies.
-
Korea Operational
Boehringer Ingelheim is actively seeking market opportunities and assets within the country of Korea.
-
Nanyang Technological University Operational
Boehringer Ingelheim and Nanyang Technological University established a new research collaboration agreement.
-
AbbVie Operational
Both companies are discussed in the context of competitive M&A strategies within the pharmaceutical market.
-
American Gastroenterological Association Operational
Boehringer Ingelheim formed a committee that included the American Gastroenterological Association.
-
ACCESS Health International Operational
Boehringer Ingelheim provides support to the ACCESS Health International forum.
-
Gainesville Shared context
Boehringer Ingelheim maintains manufacturing operations within the geographic context of Gainesville.
-
GSK Operational
The entities are observed to be competitors in the pharmaceutical market, facing shared product liability risks.
-
Microsoft Operational
Microsoft and Boehringer Ingelheim are engaged in a partnership to explore digital patient twins for clinical development.
-
Las Vegas Shared context
Boehringer Ingelheim was observed operating in Las Vegas for a clinical conference.
-
Pulmonary Fibrosis Foundation Operational
PFF and Boehringer Ingelheim are collaborating as members of the PROGRESS-PPF initiative.
-
Philippines Shared context
Boehringer Ingelheim operates within the Philippines, providing preventive care information to pet owners.
-
Georgia Shared context
Boehringer Ingelheim maintains ongoing operations and investments within the state of Georgia.
-
Eli Lilly and Company Operational
Both pharmaceutical companies are currently reducing their presence in European markets.
-
Kimberly Powell Mentioned together
No evidence provided linking Boehringer Ingelheim and Kimberly Powell.
History
Events by the month they beganNovember 2026
3 events- Zealand Pharma and Boehringer Ingelheim discussed metabolic strategies and opened a new research hub in Cambridge.
- Matthew Hall serves as Executive Director of Corporate Development at Boehringer Ingelheim.
- ACCESS Health International convened a health forum in the Philippines, which was supported by Boehringer Ingelheim.
October 2026
6 events- Microsoft and Boehringer Ingelheim announced a partnership to explore digital patient twins for clinical development.
- Boehringer Ingelheim formed a new committee including the American Liver Foundation, American Gastroenterological Association, and several key individuals.
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.
- Boehringer Ingelheim and Nanyang Technological University have established a new research collaboration agreement.
- Boehringer Ingelheim and SLR Consulting have partnered to develop an energy transformation programme.
- A foundation, involving Boehringer Ingelheim, addresses malnutrition and health issues in Colombia through social innovation hubs.
September 2026
5 events- Sheila Denton was appointed as General Counsel & Corporate Secretary at Boehringer Ingelheim.
- Boehringer Ingelheim and Palatin Technologies reported $13.2 million in revenue from their Fiscal 2026 collaboration.
- Boehringer Ingelheim reminds pet owners about preventive care in the Philippines.
- Commission approved Boehringer storage structure plans and safety improvements for a railroad crossing.
- AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.
Show 3 earlier months
August 2026
3 events- Boehringer supplies vaccines to England and collaborates with the VMD, leading to disease spread into Scotland.
- Boehringer Ingelheim opened a new U.S. Animal Health headquarters in Gainesville and continues to invest in Georgia operations.
- WEG S.A., a Brazilian electric motor manufacturer, is linked to wealth derived from an inherited stake.
July 2026
3 eventsJune 2026
13 events- Major pharmaceutical companies, including Eli Lilly, AstraZeneca, and Boehringer Ingelheim, are adjusting investments and operations in Europe.
- Boehringer Ingelheim and Immunai announced a collaboration focused on T-cell targets for drug discovery.
- Boehringer Ingelheim is seeking first-in-class assets in Korea.
- Boehringer Ingelheim announced a partnership with Americares that aims to improve global access to medicine.
- Proposed German drug pricing legislation is causing investment cuts and expansion cancellations for pharmaceutical companies.
- German drug pricing policy creates investment risk for pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim.
- German drug pricing reform is causing Eli Lilly and Boehringer Ingelheim to withdraw from European markets.
- Dr. Kirk Shepard joined BP Logix's Life Sciences Strategic Advisory Board, leveraging his extensive background in the pharmaceutical industry.
- Elanco, Zoetis, and Boehringer Ingelheim are noted for their leadership in the veterinary dermatology market.
- Jyothis George held leadership roles at Amgen, Novo Nordisk, and Boehringer Ingelheim, driving strategic decisions on target indications and clinical trials.
- Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement, receiving FDA feedback on a Pre-IND Briefing Document.
- The FDA approved the Oncomine Dx Target Test, which identifies candidates for Boehringer Ingelheim's HERNEXEOS.
- Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.